| Abstract: |
The 4th international melanoma congress of the Society for Melanoma Research (SMR), organized by Marianne Berwick (University of New Mexico), Paul Chapman (Memorial Sloan-Kettering Cancer Center), Rene Gonzalez (University of Colorado) and Ze'ev Ronai (Burnham Institute), was held at the Marriott Hotel in downtown New York on November 2007. The congress was attended by a record high number of attendees (over 500 delegates) who joined to discuss recent advances in melanoma biology and therapy. About 40% of the participants arrived from 39 countries, a testament to the high impact of this annual gathering on the international melanoma community. Over 120 of the participants were students or postdoctoral fellows, representing a most impressive fraction of young scientists engaged in melanoma research. The meeting consisted of more than 50 plenary and minisymposia presentations, stimulating the exchange of unpublished data and novel ideas, and helping to forge new collaborations that are anticipated to facilitate significant advances in basic, translational and clinical melanoma research. Another major focus of this meeting was over 160 posters, which were heavily attended and provided an effective forum for extensive informal discussions. This report will highlight the major scientific themes and advances of this most successful meeting, and provide a useful perspective on the current state of melanoma research, as well as where the field should be heading. © 2008 The Authors. |
| Keywords: |
signal transduction; unclassified drug; gene mutation; fludarabine; clinical trial; disease course; sorafenib; monotherapy; nonhuman; conference paper; paclitaxel; adjuvant therapy; rituximab; temozolomide; cancer staging; antineoplastic agent; protein function; cell proliferation; phenotype; animals; cell survival; cell cycle progression; carboplatin; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; melanoma; metastasis; apoptosis; biomedical research; breast cancer; gene expression; cell maturation; protein kinases; sun exposure; melanocyte; melanocytes; incidence; combination chemotherapy; cell differentiation; mutational analysis; risk factor; transcription factors; cell transformation, neoplastic; monoclonal antibody; gene expression regulation, neoplastic; medical research; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; neoplasm metastasis; medical society; tamoxifen; tumor immunity; melanoma antigen; cyclin dependent kinase inhibitor 2a; tumor growth; micrornas; trastuzumab; microphthalmia associated transcription factor; guanine nucleotide binding protein; comparative genomic hybridization; cell aging; b raf kinase; g protein coupled receptor; international cooperation; wnt3a protein; plx 4032; n (2,3 dihydroxypropoxy) 3,4 difluoro 2 (2 fluoro 4 iodoanilino)benzamide; cyclin dependent kinase inhibitor 2b; cyclin dependent kinase inhibitor 1; az 26244; monoclonal antibody 9.2.27; monoclonal antibody ta99; raf 265; sta 4783; xl 820; societies, scientific
|
